Dr. Dan | Obesity Expert

Dr. Dan, who describes himself as a pharmacist turned obesity expert, covers nausea as a side effect of GLP-1 receptor agonists such as Ozempic, Wegovy, Saxenda and Trulicity.

1. 0:00 Introduction
2. 0:57 What Is Nausea? (Definition)
3. 2:07 Medical Alert: When to Go to the ER
4. 2:56 Why GLP-1s Cause Nausea (The Science)
5. 5:03 The #1 Myth: Does Nausea Cause Weight Loss?
6. 5:56 Stop Fighting Through It , Your Comfort Matters
7. 6:20 How to Manage Nausea (Overview)
8. 6:40 Fix #1: Smaller, More Frequent Meals

• Side effects mentioned: nausea, vomiting and heartburn or reflux
• Who is speaking: Clinician (Dr. Dan)

In this video, Dr. Dan, an obesity expert, gives an overview of Mounjaro (tirzepatide) for people who have been prescribed it or are thinking of asking a doctor about it.

1. 0:00 Why you NEED to watch this before starting Mounjaro
2. 0:28 Mounjaro approval status & off-label use for weight loss
3. 1:11 The "twin incretin molecule" , what makes Mounjaro different
4. 2:30 How GIP protects your pancreas & controls blood sugar
5. 3:05 Insulin & fat gain , the myth vs. the science
6. 5:24 Special populations: pregnancy, breastfeeding & thyroid canc
7. 6:11 Does Mounjaro damage your kidneys? (The real answer)
8. 7:30 Common side effects & how to manage them

• Doses mentioned: 15 mg
• Side effects mentioned: nausea, vomiting, constipation, diarrhea, dehydration, gallbladder and pancreatitis
• Who is speaking: Clinician (Dr. Dan)

Dr. Dan, who describes himself as a pharmacist and weight management specialist, explains what Ozempic is and why it was in the news at the time of filming.

1. 0:00 <Untitled Chapter 1>
2. 0:08 Ozempic
3. 1:31 What Is Ozempic
4. 2:25 Victoza
5. 4:16 Step Trials
6. 5:18 Oral Formulation of Ozempic
7. 5:43 What Is Glp1
8. 12:29 Conclusion

• Doses mentioned: 2.4 mg
• Side effects mentioned: nausea and vomiting
• Who is speaking: Clinician (Dr. Dan)

A clinician explains how Ozempic works and what the evidence says. It has no captions we could read, so this is drawn from its title and description.

• Who is speaking: Clinician (Dr. Dan)

In this video, Dr. Dan, who describes himself as a pharmacist and obesity expert, covers constipation and diarrhea that can come with GLP-1 receptor agonists such as Ozempic, Saxenda and Trulicity.

• Side effects mentioned: nausea, constipation, diarrhea, bloating and dehydration
• Who is speaking: Clinician (Dr. Dan)

A clinician demonstrates the Mounjaro injection, step by step. It has no captions we could read, so this is drawn from its title and description.

• Who is speaking: Clinician (Dr. Dan)

Dr. Dan, who describes himself as a pharmacist turned obesity expert, covers fatigue that can occur with GLP-1 receptor agonists such as Saxenda, Wegovy and Ozempic.

1. 0:00 <Untitled Chapter 1>
2. 2:38 What We Mean by Fatigue
3. 3:21 Glp-1 Receptor Agonists
4. 9:38 Determine How Many Calories You Should Be Eating

• Side effects mentioned: vomiting and fatigue
• Who is speaking: Clinician (Dr. Dan)

Dr. Dan, who presents as an obesity expert, walks through the SELECT trial, published in the New England Journal of Medicine. He explains that earlier obesity medications and lifestyle change alone have a weak record on heart risk.

1. 0:00 Obesity and heart risk
2. 0:30 Limitations of past treatments
3. 1:32 GLP-1 medication benefits
4. 2:58 The select trial explained
5. 4:20 Study methodology
6. 5:39 Participant demographics
7. 6:46 Trial results
8. 9:29 Specific risk reductions

• Doses mentioned: 2.4 mg
• Side effects mentioned: gallbladder
• Who is speaking: Clinician (Dr. Dan)

Dr. Dan, an obesity-focused physician, says the so-called oral Ozempic is oral semaglutide, which is already sold as Rybelsus for diabetes at up to 14 milligrams a day.

1. 0:50 Dose change
2. 2:30 The trials
3. 5:28 Side effects
4. 6:37 The trials
5. 8:05 Dose change

• Doses mentioned: 14 mg, 25 mg and 50 mg
• Side effects mentioned: gallbladder
• Who is speaking: Clinician (Dr. Dan)

Dr. Dan, who presents as an obesity expert, explains why some people taking Wegovy or Zepbound do not lose weight.

1. 0:00 Intro
2. 1:29 The 3 Types of NonResponse
3. 5:07 The Quick Fix Seekers
4. 5:53 Book a Free Consultation
5. 7:24 Magical
6. 8:07 Effort
7. 10:58 Conclusion

• Who is speaking: Clinician (Dr. Dan)

A clinician looks at what life on Wegovy is like. Also covers stopping and maintenance.

• Who is speaking: Clinician (Dr. Dan)

A clinician explains how Wegovy works and what the evidence says. It has no captions we could read, so this is drawn from its title and description.

• Who is speaking: Clinician (Dr. Dan)

In this video, Dr. Dan, who presents himself as an obesity expert, says people taking Ozempic, Wegovy or Zepbound can lose a large share of their weight loss as muscle, up to 40% by his account, if they do not do resistance training.

1. 0:00 Are you losing fat AND muscle mass?
2. 1:16 How do GLP-1s work?
3. 2:11 Meet Linda
4. 2:39 Promo: Book a 1:1 with Dr. Dan
5. 3:13 1 Resistance training 2-3x/week
6. 4:25 2 Prioritize protein
7. 5:09 3 Smart cardio
8. 5:59 4 Eat enough

• Side effects mentioned: fatigue and muscle loss
• Who is speaking: Clinician (Dr. Dan)

A clinician explains how Ozempic works and what the evidence says. It has no captions we could read, so this is drawn from its title and description.

• Who is speaking: Clinician (Dr. Dan)

A clinician explains how Ozempic works and what the evidence says. It has no captions we could read, so this is drawn from its title and description.

• Who is speaking: Clinician (Dr. Dan)

Dr. Dan, who presents as an obesity expert and runs a pharmacy in Alberta, Canada, explains how he approaches switching from other GLP-1 medications to Mounjaro or Zepbound. He opens with a table sorting the products by molecule.

1. 0:00 Intro
2. 0:45 Table
3. 4:30 Switching

• Doses mentioned: 1 mg, 2 mg, 2.5 mg and 5 mg
• Who is speaking: Clinician (Dr. Dan)

Dr. Dan, an obesity expert, answers a question he says he gets often from people on Ozempic, Wegovy or Mounjaro: what dose to use once a target weight is reached. He says people ask about a lower maintenance dose for several reasons.

1. 0:02 Dose change
2. 3:18 The trials
3. 4:42 Dose change

• Doses mentioned: 1.7 mg and 2.4 mg
• Who is speaking: Clinician (Dr. Dan)

A clinician talks about stopping Wegovy and what came after. It has no captions we could read, so this is drawn from its title and description.

• Who is speaking: Clinician (Dr. Dan)

Dr. Dan, who describes himself as a pharmacist and weight management specialist, gives his opinion on Rybelsus, the tablet form of semaglutide that he says people call oral Ozempic. He explains that Rybelsus is taken once a day, while Ozempic is an injection taken once a week.

1. 0:00 Intro
2. 1:25 What is Rybelsus
3. 4:00 How does it work
4. 8:34 Why Ozempic
5. 11:05 Conclusion

• Doses mentioned: 2.4 mg and 14 mg
• Who is speaking: Clinician (Dr. Dan)

Dr. Dan, an obesity expert, explains how he would help a patient stop a medication like Wegovy or Zepbound while trying to keep the weight off. He says he generally does not recommend stopping, because he describes these drugs as safe, effective and usable long term.

1. 0:00 The reality of weight regain
2. 2:00 Biology and weight maintenance
3. 3:44 Preparing to stop medication
4. 6:29 Transitioning diet habits
5. 8:00 Medication tapering strategy
6. 10:21 Activity and lifestyle habits
7. 11:49 Expectations and final advice

• Doses mentioned: 1.7 mg
• Side effects mentioned: muscle loss
• Who is speaking: Clinician (Dr. Dan)

In this video, Dr. Dan, who presents as an obesity expert, tells viewers that returning food noise while on tirzepatide (Zepbound) does not mean the medication has stopped working.

1. 0:00 Is food noise back on Tirzepatide?
2. 1:23 What happens when you take Tirzepatide?
3. 2:21 When food noise comes back
4. 2:59 Pause, name it and reframe it
5. 4:12 Promo: Book a 1:1 with Dr. Dan
6. 5:05 If your food noise is increasing: # 1 Sleep
7. 5:24 2 Hydration levels
8. 5:38 3 Protein intake

• Side effects mentioned: fatigue
• Who is speaking: Clinician (Dr. Dan)

A clinician explains how a GLP-1 works and what the evidence says. It has no captions we could read, so this is drawn from its title and description.

• Who is speaking: Clinician (Dr. Dan)

Dr. Dan, who describes himself as a pharmacist and obesity expert, argues that the idea of "graduating" from a GLP-1 medication is a myth promoted by diet culture. He builds his case on the SURMOUNT maintain trial.

1. 0:00 The graduation fantasy
2. 0:53 Why the “wean off” narrative is a lie
3. 1:43 SURMOUNT MAINTAIN trial data
4. 2:43 Trial results
5. 3:47 The biology behind the regain
6. 4:50 GLP-1s modulate your systems
7. 6:49 The trial’s key takeaways
8. 7:05 1⃣ The Full Guard

• Doses mentioned: 5 mg and 15 mg
• Who is speaking: Clinician (Dr. Dan)

In this video, Dr. Dan, who presents as an obesity expert, responds to news that the European Union is investigating whether semaglutide, the molecule in Ozempic, is linked to depression and suicidal thoughts in some people.

• Side effects mentioned: fatigue
• Who is speaking: Clinician (Dr. Dan)

In this short video, Dr. Dan, who describes himself as a pharmacist and obesity expert, explains how Saxenda, Ozempic and Wegovy work. He says all three are GLP-1 receptor agonists.

1. 0:18 How it works
2. 1:50 Side effects
3. 2:34 How it works

• Who is speaking: Clinician (Dr. Dan)

A clinician talks about food noise, cravings and mood on Ozempic. Also covers mood and mental health.

• Who is speaking: Clinician (Dr. Dan)

Dr. Dan, who presents on the Dr. Dan | Obesity Expert channel, addresses people who started a GLP-1 medication in the new year, lost several pounds in week one, and then saw the scale stall or tick up in week two.

1. 0:00 <Untitled Chapter 1>
2. 1:34 The “Water Illusion” – why fast Week 1 losses are mostly wat
3. 2:28 How GLP-1 medications change insulin, kidneys, and fluid bal
4. 3:25 The “thermostat” effect (adaptive thermogenesis) that makes
5. 4:48 Why “Quitter’s Day” and the drift in habits hit right as the
6. 6:55 A step-by-step “Don’t Quit Protocol” so you can keep going c

• Point in the journey: Week 2
• Side effects mentioned: fatigue
• Who is speaking: Clinician (Dr. Dan)

In this video, Dr. Dan, who presents as an obesity expert, lists six mistakes he says stall progress for people taking tirzepatide (which he also calls Zepbound), plus a bonus mistake.

1. 0:00 Have you been ghosted by your tirzepatide?
2. 0:37 6 Treating tirzepatide a magic wand
3. 1:16 5 Ignoring the loss of muscle
4. 1:45 4 Not managing hunger
5. 2:25 Promo: Book a 1:1 with Dr. Dan
6. 2:52 3 Eating too little too soon
7. 3:30 2 Not managing gut side effects
8. 4:02 1 Flying solo

• Side effects mentioned: muscle loss
• Who is speaking: Clinician (Dr. Dan)

In this video, Dr. Dan, an obesity expert, argues that watching the number on the scale is not enough when losing weight.

1. 0:00 Intro
2. 1:31 Importance of Muscle Mass
3. 4:02 Exercise and Protein
4. 5:57 Protein Calculator
5. 9:42 Outro

• Side effects mentioned: muscle loss
• Who is speaking: Clinician (Dr. Dan)

Dr. Dan, who presents as an obesity expert, explains what Foundeo (orforglipron) is and whether people on injectable GLP-1 medications should switch to it. He says it is an oral, non-peptide small molecule that binds GLP-1 receptors.

1. 0:00 Foundayo - new GLP-1 pill
2. 0:31 What is Foundayo?
3. 0:56 Oral Semaglutide / Oral Wegovy
4. 1:50 Foundayo’s big advantages
5. 2:35 How does it compare to other GLP-1s?
6. 3:54 A pill can’t skip the “Liver Check”
7. 5:31 Small molecule concerns
8. 6:12 Drug interactions

• Prices mentioned: $350 a month
• Who is speaking: Clinician (Dr. Dan)

Dr. Dan gives an update on whether GLP-1 medications such as Wegovy and Ozempic are linked to depression and suicidal ideation. He explains that health regulators, including the FDA and the European medicines agencies, have been investigating case reports of this link.

1. 0:00 GLP-1 safety concerns
2. 1:00 Obesity and mental health
3. 3:14 New study on suicide risk
4. 7:10 Study limitations
5. 9:21 Conclusion and resources

• Who is speaking: Clinician (Dr. Dan)

A clinician looks at what life on Ozempic is like. It has no captions we could read, so this is drawn from its title and description.

• Who is speaking: Clinician (Dr. Dan)

In this video, Dr. Dan, who presents as an obesity expert, introduces orforglipron, an oral GLP-1 type medication he says is coming to market. He explains that it is a nonpeptide GLP-1 receptor agonist, meaning it acts on the GLP-1 receptor but is not the full natural hormone.

1. 0:00 Intro
2. 0:30 Ribelis
3. 1:28 Orforglipron
4. 5:38 Study results
5. 6:55 Reference point
6. 7:43 Results
7. 9:04 Conclusion

• Who is speaking: Clinician (Dr. Dan)

According to the video, Dr. Dan walks through a post hoc analysis of the SURMOUNT-4 trial, which looked at what happens when people stop Zepbound. Everyone in the trial took Zepbound for 36 weeks with lifestyle coaching.

1. 0:00 The truth about stopping Zepbound (No-fluff reality check)
2. 0:56 Why willpower isn't enough
3. 1:34 SURMOUNT-4 data: what happens when the meds stop?
4. 2:00 The 82.5% regain stat: understanding the "rebound"
5. 3:58 Beyond the scale: blood pressure, A1c, and metabolic health
6. 4:51 Obesity is chronic: why short-term fixes fail
7. 7:20 3 actionable steps to protect Your progress
8. 7:54 Step #2: muscle protection (protein & resistance)

• Side effects mentioned: fatigue
• Who is speaking: Clinician (Dr. Dan)

In this video, Dr. Dan, a pharmacist who describes himself as an obesity expert, answers a common question: if Wegovy or Mounjaro is working, why not take more than the prescribed dose to get more benefit?

1. 0:02 Dose change
2. 3:13 How it works
3. 4:57 Dose change
4. 10:04 Wrapping up

• Doses mentioned: 2 mg and 2.4 mg
• Who is speaking: Clinician (Dr. Dan)

In this video, Dr. Dan, who describes himself as an obesity expert, discusses a new post hoc analysis of the STEP UP trial, a randomized controlled trial of high-dose Wegovy up to 7.2 mg once a week.

1. 0:00 The 28% headline that's messing with your head
2. 0:53 What the STEP UP trial actually says
3. 1:39 70% of users are not Rapid Responders
4. 2:04 Why do some take longer to lose weight than others?
5. 3:07 The Volume Knob: Your brain on Wegovy
6. 4:26 The real cost of 7.2mg (yellow flag)
7. 7:33 The Steady Response Strategy
8. 7:55 2⃣ Audit the Software

• Doses mentioned: 2.4 mg and 7.2 mg
• Side effects mentioned: muscle loss and gallbladder
• Who is speaking: Clinician (Dr. Dan)

In this video, Dr. Dan of the channel Dr. Dan | Obesity Expert says that most people regain weight after stopping weight loss medications such as Wegovy or Zepbound, and that the regain is faster than many expect.

1. 0:00 The regain nobody warns you about
2. 1:41 The data: how fast does weight come back?
3. 4:25 Why it happens: the "bouncer" analogy
4. 7:15 3 exit plans (don't quit cold turkey!)
5. 9:39 Dr. Dan's Empowerment Hub

• Who is speaking: Clinician (Dr. Dan)

Dr. Dan, who describes himself as an obesity expert, explains why real-world results with Wegovy can differ from what randomized controlled trials report.

1. 0:00 Trial results overview
2. 0:50 Rigors of clinical trials
3. 2:35 Real-world vs trial data
4. 3:36 Real-world study findings
5. 5:28 Comparing results
6. 6:32 Study insights and tools
7. 8:11 Study strengths
8. 9:11 Limitations and conclusion

• Doses mentioned: 2.4 mg
• Who is speaking: Clinician (Dr. Dan)

In this video, Dr. Dan, who presents as an obesity expert, asks whether semaglutide (which he calls Wegovy) helps or harms the kidneys. He says the medication does not directly damage the kidneys.

1. 0:00 Kidney risks and medications
2. 1:34 Introduction to the flow trial
3. 2:38 Study design and participants
4. 3:54 Main trial outcomes
5. 6:02 Secondary findings
6. 7:58 Impact on kidney function
7. 9:30 Mechanisms and safety
8. 11:32 Conclusion and summary

• Side effects mentioned: diarrhea and dehydration
• Who is speaking: Clinician (Dr. Dan)

In this video, Dr. Dan, who says he has worked with hundreds of patients on GLP-1 medications, argues that feeling sick is not required for the drugs to work.

1. 0:00 The Sickness Myth: Does nausea = results?
2. 0:50 Why GLP-1 medications cause GI side effects
3. 2:33 Zepbound vs. Wegovy: The GIP Advantage explained
4. 3:41 The GI Stability Protocol
5. 3:55 1: Micro meals
6. 4:14 2: Pre-existing flag
7. 4:50 3: Fiber not processed
8. 5:13 4: Watch the Gravol

• Side effects mentioned: nausea, vomiting, sulfur burps and bloating
• Who is speaking: Clinician (Dr. Dan)

In this holiday-season video, Dr. Dan says that most people taking GLP-1 medications such as Ozempic, Wegovy, Zepbound or Mounjaro for obesity are not banned from drinking alcohol, but that the experience changes.

1. 0:00 The Holiday Drinking Dilemma
2. 0:45 The Biology: Why Alcohol Hits Different on GLP-1s
3. 1:45 The "2AM Pizza Problem" (Cravings & Control)
4. 2:15 Dr. Dan's Holiday Drinking Playbook (5 Rules)
5. 4:06 WARNING: Diabetes & Hypoglycemia Risks
6. 4:35 HARD NO: Pancreatitis & Liver Disease

• Side effects mentioned: nausea, vomiting and pancreatitis
• Prices mentioned: $15 a month and $145 a year
• Who is speaking: Clinician (Dr. Dan)

In this live stream, Dr. Dan, a pharmacist in Calgary, Alberta, first spends about ten minutes on compounded semaglutide. He says compounded versions appeared because of shortages of Ozempic, Wegovy and Mounjaro and because of high US prices.

1. 6:15 Cost and insurance
2. 10:28 Stopping and maintenance
3. 23:41 Food, protein and eating
4. 49:41 Weigh-in and results
5. 55:59 Dose change
6. 1:02:56 Cost and insurance
7. 1:12:26 Dose change

• Doses mentioned: 0.25 mg and 2.4 mg
• Side effects mentioned: fatigue, muscle loss and gallbladder
• Who is speaking: Clinician (Dr. Dan)

Dr. Dan, an obesity expert, takes up the question of whether Wegovy, Ozempic and related GLP-1 medications cause depression or suicidal ideation. He says he has covered the topic twice before but returns to it because of two news stories published about two weeks apart.

1. 0:00 Conflicting health news
2. 0:26 Analyzing the media reports
3. 1:58 WHO database study analysis
4. 4:35 Randomized control trial data
5. 7:34 Final conclusion and advice

• Who is speaking: Clinician (Dr. Dan)

According to the video, the Attain Maintain trial tested whether people who had lost weight on an injection could switch to the once-daily pill orforglipron.

1. 0:00 Can you switch from injections to a pill without consequence
2. 1:36 What is orforglipron aka Foundayo?
3. 2:05 SURMOUNT-5 trial cohorts
4. 2:49 ATTAIN MAINTAIN study data breakdown and results
5. 4:54 Orforglipron's biological ceiling
6. 6:27 The weight loss rule aka metabolic adaptation
7. 7:12 Current weight loss receptors and biological counterforces
8. 8:34 A practical approach to weight loss and weight regain

• Who is speaking: Clinician (Dr. Dan)

A clinician talks about food noise, cravings and mood on a GLP-1. Also covers stopping and maintenance and how it works.

• Who is speaking: Clinician (Dr. Dan)